Clinton campaign's 'war with pharma!!' went official with last year's stock-busting tweet: WikiLeaks

Democratic presidential candidate Hillary Clinton and her running mate, Tim Kaine.

When a single tweet from presidential candidate Hillary Clinton sent biopharma shares tumbling last fall, her campaign staff reacted with glee. Soon after, former Health and Human Services Secretary Kathleen Sebelius cheered Clinton on, too.

Industry watchers know what’s happened since--Clinton has rolled out a series of proposals to control drug prices, and one of her follow-up tweets in August triggered another selloff in biotech shares. Now, thanks to WikiLeaks, we know some of the behind-the-scenes chatter in the Clinton campaign as her pharma-pricing crusade began.

“We have started the war with pharma!!” wrote Senior Policy Advisor Ann O’Leary, on Monday, Sept. 21, 2015 as the candidate’s Sunday tweet was reverberating through the drug industry, according to a WikiLeaks extract first reported by Endpoints News.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Clinton had dispatched the now-famous tweet in response to news that then-Turing Pharmaceuticals CEO Martin Shkreli had engineered a 5,600% price hike on a toxoplasmosis drug, Daraprim. That hike, along with Shkreli’s defiant defense on Twitter and television afterward, set fire to a drug pricing debate that’s still raging.

O’Leary forwarded a USA Today story to Campaign Manager John Podesta. The story cited “a 21-word tweet” from Clinton as the weight dragging down biotech stocks, and the rest of the market with them.

Two days later, in an email to Podesta, Sebelius added insurers into her own high-five to the campaign, but specifically called out drugmaker execs, too. “Good stuff on drugs and insurers. Glad she's taking on Pharma--deaf ears among CEOs and they are just wrong,” Sebelius wrote in a Sept. 23, 2015, email to Podesta.

Sebelilus also was emphatic in her support for Medicare price negotiation, one of the pharma pricing measures Clinton had proposed after her Twitter promise.

“Should remind folks that VA can negotiate for drugs, Governors negotiate for Medicaid drugs, but Medicare, the largest purchaser, is forbidden by law,” Sebelius wrote.

“So seniors pay highest prices in world, and companies take profits, often from discoveries that started with NIH funding--a lose/lose!!!” she added.

Sebelius’ message echoes criticism in Congress as Senate and House committees have investigated a series of price increases, by Turing, then Valeant Pharmaceuticals, and, most recently, Mylan. The pharma industry says the egregious price hikes reported in the media aren’t representative of the rest of the industry, and actions that depress drugmakers’ ability to profit in the U.S. threaten R&D funding and lifesaving innovations. Pfizer CEO Ian Read, for one, has called Clinton’s drug-pricing proposals a disaster for innovation.

Allergan chief Brent Saunders, however, has called on the industry to police itself. In a blog post about biopharma’s “social contract,” Saunders pledged that Allergan would increase prices only once per year, by less than 10%. Some companies--such as Ariad Pharmaceuticals, recently called out for its fourth price hike in 2016--raise prices multiple times each year.

Special Report: 10 big brands keep pumping out big bucks, with a little help from price hikes

Related Articles:
Pfizer CEO calls Clinton drug plan 'very negative for innovation'
Allergan CEO swears off big price hikes in manifesto on pharma's 'social contract'
Hillary's latest drug-price tweet put the fear of government action into biopharma stocks
Amid still-raging EpiPen scandal, Clinton rolls out plan to fight drug price hikes
Novartis CEO predicts drug pricing overhaul in U.S. after the election, whoever wins

Suggested Articles

Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo—and it’s bringing in Bayer to help.

When AstraZeneca sold its Avlon, England plant in 2016, it thought its liabilities were over. Former employees said the drugmaker broke its promises.

Pharmacy chain Rite Aid has partnered with Google to have their drug recycling stations easily searchable on Google Maps.